In humans, anti-IL-17A antibodies have shown positive clinical responses and good safety in patients with active rheumatoid arthritis (RA) in randomized, double-blinded proof-of-concept trials [10], [11], suggesting that targeting of IL-17A is a promising therapeutic approach against human autoimmune disease, such as RA. This evidence concerns the gene IL17A and autoimmune disease.